OncoDesign will be in charge of research activities up to the selection of preclinical candidates, notably at its research site in Les Ulis. More specifically, the group will work on LRRK2 kinase inhibitors, a high-potential target for the treatment of this disease, with molecules from its Nanocyclix® platform.
This collaboration will be funded by Servier, which has an exclusive option for a worldwide licence for the potential drug candidates for treating Parkinson's disease, resulting from the programme, which can be exercised as soon as the research programme enters Phase I.
Upon signing the partnership, Oncodesign received an initial payment of €3m and will receive annual funding of the same amount. In total, Servier could pay Oncodesign up to €320m in milestone payments, in addition to royalties on sales of the drugs from this programme.
After having notably accompanied OncoDesign in several acquisitions, its IPO and the signing of various partnership agreements related to other proprietary programmes in connection with its "Drug Discovery" business, LAMY LEXEL once again advised the company when negotiating this contract. Aurélie DANTZIKIAN FRACHON, associate lawyer, and Manon POURCHER, associate director, of the Contract, Competition and Intellectual Property Department at LAMY LEXEL, assisted OncoDesign in this positioning strategy, in the drafting and negotiation of this major partnership.
OncoDesign thus confirms its role as a leading partner for players in the pharmaceutical industry.